That facility is located in Holly Springs, N.C., and is owned by Novartis of Basel, Switzerland. It can now manufacture cell-based vaccine against seasonal as well as pandemic influenza viruses.
With the approval of manufacturing in the Holly Springs facility, the capacity for seasonal influenza vaccine production in the United States can increase by at least 50 million doses.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
